Analyzing R&D Budgets: Amgen Inc. vs BioMarin Pharmaceutical Inc.

Biotech Giants' R&D: Amgen vs BioMarin Over a Decade

__timestamp	Amgen Inc.	BioMarin Pharmaceutical Inc.
Wednesday, January 1, 2014	4297000000	461543000
Thursday, January 1, 2015	4070000000	634806000
Friday, January 1, 2016	3840000000	661905000
Sunday, January 1, 2017	3562000000	610753000
Monday, January 1, 2018	3737000000	696328000
Tuesday, January 1, 2019	4116000000	715007000
Wednesday, January 1, 2020	4207000000	628116000
Friday, January 1, 2021	4819000000	628793000
Saturday, January 1, 2022	4434000000	649606000
Sunday, January 1, 2023	4784000000	746773000

Unleashing the power of data

A Decade of Innovation: Amgen Inc. vs BioMarin Pharmaceutical Inc.

In the ever-evolving landscape of biotechnology, research and development (R&D) are the lifeblood of innovation. Over the past decade, Amgen Inc. and BioMarin Pharmaceutical Inc. have demonstrated contrasting strategies in their R&D investments. From 2014 to 2023, Amgen consistently allocated a significant portion of its budget to R&D, peaking in 2021 with a 35% increase from its 2017 low. Meanwhile, BioMarin's R&D spending grew steadily, culminating in a 62% rise by 2023 compared to 2014. This divergence highlights Amgen's focus on maintaining a robust pipeline, while BioMarin's strategy appears to be one of gradual expansion. As the biotech industry continues to grow, these investment patterns may offer insights into each company's future innovations and market positioning.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025